论文部分内容阅读
目的 研究恶性卵巢肿瘤组织中ＣＤ４４ Ｖ６ 的表达及其临床意义。方法 采用免疫组织化学和ＲＴＰＣＲ 方法，检测４１ 例恶性卵巢肿瘤、２０ 例良性卵巢肿瘤和２１ 例正常卵巢组织中ＣＤ４４ Ｖ６ 基因及基因蛋白的表达情况，并分析相关的临床病理因素。结果 恶性组ＣＤ４４Ｖ６ 基因蛋白表达阳性率明显高于良性组和正常组；而ＣＤ４４ Ｖ６ 基因扩增则恶性组和良性组高于对照组，良、恶性组间无显著性差异；有转移者的ＣＤ４４ Ｖ６ 基因及ＣＤ４４ Ｖ６ 蛋白阳性率显著高于无转移者， 转移灶阳性率高于原发灶；ＣＤ４４ Ｖ６ 蛋白阳性表达者的近期疗效比阴性者差；ＣＤ４４ Ｖ６ 阳性表达率与临床期别有一定关系，但与病理类型、组织学级别无关。结论 ＣＤ４４ Ｖ６ 与肿瘤的发生、发展相关；与卵巢恶性肿瘤的浸润和转移相关，可作为预测肿瘤转移的指标；与近期疗效有关，可作为评估患者预后的指标。
Objective To study the expression of CD44 V6 in malignant ovarian tumor and its clinical significance. Methods Immunohistochemistry and RTPCR method were used to detect the expression of CD44 V6 gene and protein in 41 cases of malignant ovarian tumor, 20 cases of benign ovarian tumor and 21 cases of normal ovarian tissue. The clinicopathological factors were analyzed. Results The positive rate of CD44V6 gene in malignant group was significantly higher than that in benign group and normal group. However, the positive rate of CD44 V6 gene in malignant group and benign group was higher than that in control group. There was no significant difference between benign and malignant groups. CD44 The positive rate of V6 gene and CD44 V6 protein was significantly higher than those without metastasis, the positive rate of metastasis was higher than that of primary tumor. The positive rate of CD44 V6 protein was lower than that of negative ones Relationship, but not with pathological type, histological grade has nothing to do. Conclusions CD44 V6 is associated with the occurrence and development of tumors. It is correlated with the invasion and metastasis of ovarian malignant tumors and may be used as an index to predict tumor metastasis. It may be used as an index to evaluate the prognosis of patients.